GlobeNewswire03.28.18
REVA Medical Inc., a developer of bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom Encore bioresorbable scaffold (“BRS”) in Switzerland. The procedure was conducted by PD Dr. med Gregor Leibundgut at Medizinische Universitätsklinik, Kantonsspital Baselland in Liestal.
“REVA’s Tyrocore polymer makes Fantom Encore the most advanced bioresorbable scaffold with x-ray visibility and the thinnest strut profile in the 2.5 mm diameter size,” said Dr. Leibundgut. “During the procedure, I experienced the flexibility and ease-of-use provided by a thinner strut profile as well as excellent scaffolding. A thinner strut profile, without compromising strength, as well as the excellent visibility of the scaffold are some of the most important improvements over first generation bioresorbable scaffolds.”
Fantom Encore is a novel BRS made from Tyrocore, REVA’s proprietary polymer designed specifically for vascular scaffolds. First generation bioresorbable scaffolds are made from two materials: polylactic acid and a magnesium alloy, which are not x-ray visible, and are limited by their thick strut profiles, approximately 150 microns. Fantom Encore is x-ray visible and offers a thin 95 micron strut profile in the 2.5 mm diameter size, which is more than a 35% reduction relative to first generation scaffolds. These features are associated with improved ease-of-use, vessel healing, and long-term clinical performance.
“Many of the physicians we work with believe that bioresorbable scaffolds are the future of coronary artery disease therapy. With its thin strut profile, x-ray visibility, and ease-of-use, Fantom Encore is delivering that future today,” said Reggie Groves, CEO, REVA Medical. “The first implant of Fantom Encore in Switzerland is an important step in expanding use of our technology and broader commercial adoption.”
“REVA’s Tyrocore polymer makes Fantom Encore the most advanced bioresorbable scaffold with x-ray visibility and the thinnest strut profile in the 2.5 mm diameter size,” said Dr. Leibundgut. “During the procedure, I experienced the flexibility and ease-of-use provided by a thinner strut profile as well as excellent scaffolding. A thinner strut profile, without compromising strength, as well as the excellent visibility of the scaffold are some of the most important improvements over first generation bioresorbable scaffolds.”
Fantom Encore is a novel BRS made from Tyrocore, REVA’s proprietary polymer designed specifically for vascular scaffolds. First generation bioresorbable scaffolds are made from two materials: polylactic acid and a magnesium alloy, which are not x-ray visible, and are limited by their thick strut profiles, approximately 150 microns. Fantom Encore is x-ray visible and offers a thin 95 micron strut profile in the 2.5 mm diameter size, which is more than a 35% reduction relative to first generation scaffolds. These features are associated with improved ease-of-use, vessel healing, and long-term clinical performance.
“Many of the physicians we work with believe that bioresorbable scaffolds are the future of coronary artery disease therapy. With its thin strut profile, x-ray visibility, and ease-of-use, Fantom Encore is delivering that future today,” said Reggie Groves, CEO, REVA Medical. “The first implant of Fantom Encore in Switzerland is an important step in expanding use of our technology and broader commercial adoption.”